Zynerba Pharmaceuticals — Investor Presentation (May 2017)
37 slides from Zynerba Pharmaceuticals's investor presentation, May 1, 2017
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Enrollment Complete for Two Phase 2 Trials; Top Line Results Expected July/August 2017
Enrollment Complete for Two Phase 2 Trials Top Line Results Expected in July/August 2017 3 Osteoarthritis — STOP Epilepsy — STAR 1 188 patients randomized (target was 180) 320 patients randomized (target was 300) * As of April 24, 2017
Slide 3: Company Highlights
Company Highlights 4 A clinical-stage specialty pharmaceutical company pioneering the development and commercialization of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in CNS and pain drug develop
Slide 4: 2017 – A Transformational Year Ahead with Multiple Near-term Milestones
2017 – A Transformational Year Ahead with Multiple Near-term Milestones Expected from Robust Pipeline 5 ZYN002 patent protected through 2030 ZYN001 patent protected through 2031 Product Candidate Indication Preclinical Phase 1 Phase 2 Next Milestones ZYN001 – THC Pro-Drug Patch ZYN002 – CBD Gel Epil
Slide 5: Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space
Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space 6 We believe CBD gel for focal seizures is a significantly de-risked lead candidate Reliable animal models show efficacy of CBD in epilepsy Third party studies have shown activity of CBD in reducing focal seizure
Slide 6: Breadth of Therapeutic Opportunities
Breadth of Therapeutic Opportunities 7 Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, mostly in the CNS and immune system. Δ9-tetrahydrocannabinol (Δ9-THC) Cannabidiol (CBD) Possible indications Fibromyalgia Neuropathic Pain Appetite Nausea and vo
Slide 7: ZYN002 – CBD Gel
ZYN002 – CBD Gel First and only patent-protected permeation-enhanced synthetic cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the epidermis and into the circulatory system 8 CBD Delivery
Slide 8: Transdermal ZYN002 vs. Oral CBD
Transdermal ZYN002 vs. Oral CBD 9 Potential Benefits of Transdermal ZYN002 vs. Oral CBD More consistent, controlled and sustained plasma level Avoids first-pass metabolism in the liver Fewer drug-drug interactions Avoids the GI tract Very low incidence of gastrointestinal events Avoids degradation o
Slide 9: Transdermal CBD Avoids Degradation of CBD to THC
Transdermal CBD Avoids Degradation of CBD to THC 10 In Vitro Study ZYN002 avoids the GI tract, maintains CBD at physiological pH and prevents degradation of CBD to THC CBD degraded to THC in simulated gastric fluid May lead to increased psychoactive effects from THC Study data (Merrick et al.) publi
Slide 10: Phase 1 Trials Safety, Tolerability and Pharmacokinetics
Trials 1 day, 7 day, and 14 day trials Subjects 98 healthy volunteers (n= 70 ZYN002; n= 28 placebo) and 22 epilepsy patients (n=16 ZYN002; n=6 placebo) Dose Daily doses levels – 50 to 504 mg CBD in 1%, 2.5% and 4.2% concentrations Safety & Tolerability ZYN002 was safe and well-tolerated at all dose
Slide 11: Why Are We Studying CBD in Epilepsy in Adults?
Why Are We Studying CBD in Epilepsy in Adults? 12 * Data per CDC and American Epilepsy Society CBD is effective in multiple animal models of epilepsy, which are highly predictive of efficacy in humans Kindling and maximal electroshock (models for focal and generalized seizures) Audiogenic, penicilli
Slide 12: ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy
ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy Based on Other CBD Trials 13 Lennox-Gastaut Syndrome Dravet Syndrome Refractory Epilepsy with Focal Seizures Type of Trial 2 Double Blind Placebo Controlled (3rd Party) Double Blind Placebo Controlled (3rd Party) STAR 1 and 2 – Un
Slide 13: Epilepsy Phase 2 Clinical Trial: Top Line Results Expected July/August 2017
Epilepsy Phase 2 Clinical Trial Top Line Results Expected in July/August 2017 14 ZYN002 High-Dose CBD 195 mg* ZYN002 Low-Dose CBD 97.5 mg* Placebo Baseline Assess seizure frequency/type Open-Label Extension Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy *In 4.2% gel ZYN002 High-Dose
Slide 14: STAR Efficacy Endpoints
STAR 1 Efficacy Endpoints 15 Primary Endpoint: Median reduction in seizure frequency per 28-day period comparing baseline with the treatment period via daily seizure diary Secondary Endpoints Proportion of patients with ≥50% reduction from baseline in seizure frequency Percent change from baseline i
Slide 15: STAR 1 Baseline Information
16 STAR 1 Baseline Information* Anti-Epileptic Drug Patients Anti-Epileptic Drug Patients Levetiracetam (Keppra) 72 Zonisamide (Zonegran) 20 Carbamazepine (Tegretol) 67 Perampanel (Fycompa) 16 Lamotrigine (Lamictal) 53 Clonazepam (Klonopin) 15 Lacosamide (Vimpat) 44 Oxcarbazepine (Trileptal) 13 Valp
Slide 16: STAR 1 & STAR 2 Enrollment Status
17 STAR 1 & STAR 2 Enrollment Status* Patients n Screened 224 Randomized 188 Still in Baseline 0 Completed STAR 1 139 Enrolled into STAR 2 135 * As of April 24, 2017
Slide 17: Why ZYN002 in Osteoarthritis?
Why ZYN002 in Osteoarthritis? 18 CBD modulates the vanilloid TRPV1 receptor which mediates antinociceptive and anti-inflammatory effects Mono-arthritic rat model provides proof of concept* ZYN002 was applied for four days after inducing arthritis in rats Significant reductions in: Swelling of knee j
Slide 18: Osteoarthritis Phase 2 Clinical Trial – STOP
Osteoarthritis Phase 2 Clinical Trial – STOP Top Line Results Expected in July/August 2017 19 Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis ZYN002 High-Dose: CBD 250 mg* ZYN002 Low-Dose: CBD 125 mg* Placebo Washout Baseline 1 week Every 12 hours for 12 weeks 7-10
Slide 19: STOP Efficacy Endpoints
STOP Efficacy Endpoints 20 Primary Endpoint: Change from baseline in the weekly mean of the 24-hour average worst pain score at Week 12 Secondary Endpoints Assessments Change from baseline in the WOMAC Pain, Stiffness, and Physical Function Subscales Weeks 4, 8, 12 Responder rate based on ≥30% reduc
Slide 20: STOP Enrollment Status and Baseline Information
21 STOP Enrollment Status and Baseline Information Worst Knee Pain Score** (During Baseline) Mean=6.8 *As of 24 March 2017 **As of 20 March 2017 Patients n* Screened 418 Randomized 320 Still in Baseline 0
Slide 21: What is Fragile X Syndrome?
What is Fragile X Syndrome? 22 Fragile X Syndrome Autism spectrum disorder Most common inherited intellectual disability Caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome Leads to dysregulation of the endocannabinoid pathway including the reduction in endogeno
Slide 22: Why ZYN002 in Fragile X Syndrome?
Why ZYN002 in Fragile X Syndrome? CBD may effectively treat Fragile X syndrome In mouse knock-out model, inhibition of the metabolism of 2-AG improves Fragile X syndrome symptoms CBD inhibits the metabolism of anandamide and 2-AG increasing availability of these cannabinoids CBD has strong anxiolyti
Slide 23: Fragile X Phase 2 Clinical Trial – FAB-C
Fragile X Phase 2 Clinical Trial – FAB – C Top Line Results Expected in 3Q17 24 Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg* Daily Screening Titration Weeks 6 to 12 Day 1 to Week 6 Open label, doses of CBD 50 mg, 100 mg, or 250 mg* Daily *In 4.2% gel Target for enro
Slide 24: FAB-C Outcome Measures
FAB – C Outcome Measures 25 Changes in Anxiety, Depression and Mood vs. Baseline as Measured by the ADAMS Scale Secondary Outcome Measures Aberrant Behavior Checklist Visual Analog Scale (VAS) to Assess Hyperactivity / Impulsivity Quality of Sleep- Sleep onset, sleep time, nighttime awakenings Prima
Slide 25: ZYN001 – THC Pro-Drug Patch
ZYN001 – THC Pro-Drug Patch 26 Patent-protected synthetic D-glyceric acid ester-Δ9-tetrahydrocannabinol in a transdermal patch Working with LTS Lohmann Therapie-Systeme AG to optimize the formulation of ZYN001 for use in a state of the art drug-adhesive matrix transdermal patch before initiating pha
Slide 26: Why a Patch?
Note: Based upon FDA approved patch products. These results are not indicative of any preclinical or clinical data for ZYN001. Why a Patch? 27 Requirement Purpose Non-oral Avoids first-pass metabolism with increased bioavailability and more consistent plasma levels Controlled More consistent, contro
Slide 27: Why THC in Fibromyalgia?
THC is a CB1 agonist Has an analgesic effect in chronic pain models Acts at many sites along pain transmission pathways Nabilone (THC analogue) in patients with fibromyalgia Third-party 4-week, randomized, double-blind, placebo-controlled trial (N=40) — significant decreases in pain scores on multip
Slide 28: THC in Neuropathic Pain
THC’s agonist effect on CB1 receptors modulates nociceptive thresholds by regulating neuronal activity Third-party randomized, double-blind, placebo-controlled crossover trial in diabetic peripheral neuropathy (DPN) demonstrated that THC is effective in reducing neuropathic pain 16 patients with DPN
Slide 29: ZYN001 – THC Pro-Drug Patch Preliminary Phase 1 Clinical Plan
ZYN001 – THC Pro-Drug Patch Preliminary Phase 1 Clinical Plan 30 Trial Patients Dosing PD Evaluations Timing Single Rising Dose Trial in Normal Subjects Pharmacokinetic profile and tolerability evaluation 32 healthy volunteers and 12 patients with fibromyalgia Single dose Cognition and attention (Tr
Slide 30: ZYN001 – THC Pro-Drug Patch Preliminary Phase 2 Clinical Plan
31 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 120 patients 12 weeks Change from baseline in Fibromyalgia Impact Questionna
Slide 31: Strong Balance Sheet Provides Expected Runway into 2019
32 Cash & cash equivalents at 12/31/2016 was $31.0 million Raised $54.3 million in net proceeds from the sale and issuance of 3.2 million common shares through secondary offering at $18.00 per share in 1Q17 Cash at 12/31/2016 plus net proceeds from Q1 raise totals $85.3 million We believe that cash
Slide 32: Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space
Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space 33 We believe CBD gel for focal seizures is a significantly de-risked lead candidate Reliable animal models show efficacy of CBD in epilepsy Third party studies have shown activity of CBD in reducing focal seizur
Slide 33: Proven Leadership in Transdermal Drug Development
Proven Leadership in Transdermal Drug Development 34 Armando Anido Chairman of the Board & Chief Executive Officer Terri Sebree President Jim Fickenscher CFO & VP Corp. Development Suzanne Hanlon General Counsel and VP, Human Resources Brian Rosenberger VP, Commercial Donna Gutterman, PharmD VP, Med
Slide 34: Scientific Advisors
Jacqueline French, MD Professor of Neurology, NYU Langone Medical Center John Messenheimer, MD Consultant, Neurologist/Epileptologist, John Messenheimer PLLC Michael Rogawski, MD, PhD Professor of Neurology, UC Davis Center for Neuroscience Rodney Radtke, MD Professor of Neurology, Duke University M
Slide 35: Investor Relations and Analyst Coverage
Investor Relations 36 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Piper Jaffray: Charles C. Duncan, PhD Oppenheimer: Derek Archila H.C. Wainwright: Corey Davis, PhD Roth: Michael Higgins Canaccord Genuity: Arlinda Lee, PhD Cantor Fitzgerald: Elemer Piros, PhD Maxim: Lauren Chung, PhD *
Slide 36: May 2017
May 2017 A clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs
Slide 37: Zynerba closing slide
je specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs May 2017
Zynerba Pharmaceuticals — Investor Presentation (May 2017) on 6ix